CD40L Inhibitor Frexalimab Demonstrates Significant Reduction of Neurofilament Light in Long-Term Extension

After 48 weeks of continued treatment, those in the high-dose frexalimab group showed a 41% reduction in neurofilament light.:

Source: Neurology Read More